Skip to main content

#161577

PaTu 8902 SMAD4 KOrec reconstituted cell line

Cat. #161577

PaTu 8902 SMAD4 KOrec reconstituted cell line

Cat. #: 161577

Availability: 8-10 weeks

Organism: Human

Tissue: Pancreas

Disease: Cancer

Model: Transgeneic

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Ji??­ Neu?žil

Institute: Institute of Biotechnology of the Academy of Sciences of the Czech Republic

Primary Citation: Ezrova et al. Oncogene. 2021 Apr, 40(14):2539-2552. PMID: 33686239

Tool Details
Handling
Related Tools
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: PaTu 8902 SMAD4 KOrec reconstituted cell line
  • Alternate name: PaTu 8902 SMAD4-deficient cells, reconstituted wt SMAD4
  • Cancer: Pancreatic cancer
  • Cancers detailed: Pancreatic ductal adenocarcinoma
  • Research fields: Cancer
  • Parental cell: PaTu 8902
  • Organism: Human
  • Gender: Female
  • Tissue: Pancreas
  • Disease: Cancer
  • Morphology: Epithelial cells
  • Growth properties: Adherent
  • Model: Transgeneic
  • Model description: SMAD4 knock-out cells, wild-type SMAD4 reconstituted using lentiviral transduction (pCDH-CMV vector)
  • Crispr: Yes
  • Conditional: No
  • Products or characteristics of interest: Stable expression of SMAD4
  • Description: SMAD4 is an important tumor suppressor involved in transforming growth factor ? (TGF?) signaling, and associated with altered mitochondrial activity. The resistance of SMAD4-deficient cells is mediated by increased mitophagic flux driven by MAPK/ERK signaling, whereas TGF?-induced resistance is autophagy-independent and linked to epithelial-to-mesenchymal transition (EMT). Mitochondria-targeted tamoxifen, a complex I inhibitor under clinical trial, overcomes resistance mediated by SMAD4-deficiency or TGF? signaling. Our data point to differential mechanisms underlying the resistance to treatment in PDAC arising from TGF? signaling and SMAD4 loss, respectively.
  • Biosafety level: 1
  • Recommended controls: PaTu 8902 SMAD4 KO

Handling

  • Growth medium: DMEM+10% FBS
  • Temperature: 37° C
  • Atmosphere: 5% CO2
  • Shipping conditions: Dry Ice
  • Storage medium: Complete medium + 10% DMSO
  • Storage conditions: Liquid Nitrogen
  • Subculture routine: Trypsin-EDTA
  • Cultured in antibiotics: Yes
  • Mycoplasma free: Yes

Related Tools

  • Related tools: PaTu 8902 SMAD4 KO cell line

References

  • Ezrova et al. Oncogene. 2021 Apr, 40(14):2539-2552. PMID: 33686240

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.